Business Context and Reporting Period
Aprea Therapeutics, Inc. (APRE) filed a Form 8-K on October 9, 2024. The Company is an emerging growth company currently finalizing its financial closing for the quarter ended September 30, 2024.
Key Financial Metrics
The filing provides preliminary, unaudited cash position data. Complete financial information, including revenue, profit, margins, and debt, is not yet available as the quarterly closing process is ongoing.
- Cash and Cash Equivalents (Preliminary): Approximately $26.2 million as of September 30, 2024.
- Cash and Cash Equivalents (Prior Quarter): Approximately $28.7 million as of June 30, 2024.
- Revenue, Profit, and Margins: Not provided in this filing.
- Debt and Liquidity: No specific debt figures provided; liquidity is indicated by the cash balance.
Material Changes
Cash Position: The Company's cash and cash equivalents decreased sequentially by approximately $2.5 million from June 30, 2024, to September 30, 2024.
Management Changes: Dr. Nadeem Mirza is stepping down as Chief Medical Officer effective October 9, 2024. He will remain with the Company until no later than December 13, 2024, to ensure a smooth transition. Dr. Phillipe Pultar has been engaged as Senior Medical Advisor.
Outlook, Risks, and Unusual Items
Preliminary Data Disclaimer: The cash figures provided are preliminary estimates subject to adjustment upon completion of the quarterly closing. The independent registered public accounting firm, EisnerAmper LLP, has not audited or reviewed this information.
Leadership Transition: The departure of the Chief Medical Officer represents a material change in executive leadership, though a transition period is planned.
Investor Verification Checklist
- Verify the final audited cash balance in the upcoming Form 10-Q for the quarter ended September 30, 2024.
- Confirm the exact departure date of Dr. Nadeem Mirza and the scope of Dr. Pultar's new role.
- Review the upcoming 10-Q for full details on operating expenses and burn rate, which are not detailed in this 8-K.